15 February 2016 - An additional benefit compared to the appropriate comparator therapies has not been established for this substance because none of the studies in the dossier is relevant to the issues.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/alirocumab-bei-hypercholesterinamie-oder-gemischter-dyslipidamie-zusatznutzen-nicht-belegt.7180.html [German]